Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Autor: Robin Deterding, Matthias Griese, Gail Deutsch, David Warburton, Emily M. DeBoer, Steven Cunningham, Annick Clement, Nicolaus Schwerk, Kevin R. Flaherty, Kevin K. Brown, Florian Voss, Ulrike Schmid, Rozsa Schlenker-Herceg, Daniela Verri, Mihaela Dumistracel, Marilisa Schiwek, Susanne Stowasser, Kay Tetzlaff, Emmanuelle Clerisme-Beaty, Lisa R. Young

Publikováno v: ERJ Open Research, Vol 7, Iss 2 (2021)

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosin

Externí odkaz: https://doaj.org/article/44d5db22b39344b2a8349a04d7f20b85

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Autor: Ulrike Schmid, Nicolaus Schwerk, Mihaela Dumistracel, Steven Cunningham, Kay Tetzlaff, Kevin R. Flaherty, Kevin K. Brown, Robin R. Deterding, David Warburton, Emmanuelle Clerisme-Beaty, Florian Voss, Gail H. Deutsch, Susanne Stowasser, Emily M. DeBoer, Lisa R. Young, Annick Clement, Matthias Griese, Daniela Verri, Rozsa Schlenker-Herceg, Marilisa Schiwek

Publikováno v: Deterding, R, Griese, M, Deutsch, G, Warburton, D, DeBoer, E, Cunningham, S, Clement, A, Schwerk, N, Flaherty, K R, Brown, K K, Voss, F, Schmid, U, Schlenker-Herceg, R, Verri, D, Dumistracel, M, Schiwek, M, Stowasser, S, Tetzlaff, K, Clerisme-Beaty, E & Young, L R 2021, ' Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease ', ERJ Open Research . https://doi.org/10.1183/23120541.00805-2020
ERJ Open Research, Vol 7, Iss 2 (2021)
ERJ Open Research
article-version (VoR) Version of Record

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dca86d3042ae77819c9bb9e7f0b5f05d
https://www.pure.ed.ac.uk/ws/files/205704745/23120_1_.pdf

Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function.

Autor: Schiwek, Marilisa, Triphan, Simon M. F., Biederer, Jürgen, Weinheimer, Oliver, Eichinger, Monika, Vogelmeier, Claus F., Jörres, Rudolf A., Kauczor, Hans-Ulrich, Heußel, Claus P., Konietzke, Philip, von Stackelberg, Oyunbileg, Risse, Frank, Jobst, Bertram J., Wielpütz, Mark O.

Publikováno v: European Radiology; Mar2022, Vol. 32 Issue 3, p1879-1890, 12p, 2 Color Photographs, 5 Charts, 1 Graph